TruScreen Limited reported unaudited consolidated earnings results for the year ended 31 March 2017. For the year, the company reported sales revenue increased 24% on the prior year to NZD 585,388 compared to NZD 472,104 a year ago. This was a result of the CE mark certification and the move to volume production of the TruScreen2 device in April 2016, as well as initial sales into global markets including Mexico, Hong Kong, Vietnam, Turkey, Ukraine, Jordan, Kazakhstan and Poland. Loss before income tax was NZD 3,540,610 against NZD 1,296,929 a year ago. Loss for the period was NZD 3,540,610 against NZD 1,286,929 a year ago. Diluted loss per share was 2.1 cents against 0.8 cents a year ago. Net cash used in operating activities NZD 2,575,584 against NZD 662,104 a year ago. Purchase of intangible asset ­ development costs of upgraded cervical cancer console was NZD 141,188 compared with NZD 2,071,893 a year ago. Purchase of equipment was NZD 6,355 compared with NZD 6,975 a year ago.